Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Inventory (2016 - 2025)

Historic Inventory for Aytu Biopharma (AYTU) over the last 11 years, with Q4 2025 value amounting to $8.7 million.

  • Aytu Biopharma's Inventory fell 2191.25% to $8.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $8.7 million, marking a year-over-year decrease of 2191.25%. This contributed to the annual value of $11.4 million for FY2025, which is 582.32% down from last year.
  • According to the latest figures from Q4 2025, Aytu Biopharma's Inventory is $8.7 million, which was down 2191.25% from $10.1 million recorded in Q3 2025.
  • Aytu Biopharma's Inventory's 5-year high stood at $16.6 million during Q1 2021, with a 5-year trough of $8.7 million in Q4 2025.
  • Over the past 5 years, Aytu Biopharma's median Inventory value was $12.9 million (recorded in 2022), while the average stood at $12.9 million.
  • In the last 5 years, Aytu Biopharma's Inventory soared by 33001.59% in 2021 and then tumbled by 3360.06% in 2022.
  • Over the past 5 years, Aytu Biopharma's Inventory (Quarter) stood at $16.6 million in 2021, then dropped by 21.79% to $13.0 million in 2022, then grew by 0.39% to $13.0 million in 2023, then dropped by 14.74% to $11.1 million in 2024, then fell by 21.91% to $8.7 million in 2025.
  • Its Inventory stands at $8.7 million for Q4 2025, versus $10.1 million for Q3 2025 and $11.4 million for Q2 2025.